Effects of Undernutrition and Predictors on the Survival Status of HIV-Positive Children after Started Antiretroviral Therapy (ART) in Northwest Ethiopia

Table 2

Clinical and immunological profiles of HIV-positive children who received ART care in selected public health facilities in Northwest Ethiopia, January 1, 2009–December 30, 2020.

Variables	Categories	Number	Frequency
Dietary counseling during follow-up	Yes	465	64.49
Admission history of SAM	Yes	128	17.75
Opportunistic infections at baseline	Yes	258	35.78
ART regimen types	D4T-3TC-NVP	48	6.66
	D4T-3TC-EFV	26	3.61
	AZT-3TC-NVP	293	40.64
	AZT-3TC-EFV	165	22.88
	TDF-3TC-EFV	104	14.42
	AZT-3TC-LPV/R	36	4.99
	ABC-3TC-NVP	25	3.47
	ABC-3TC-EFV	24	3.33
ART regimen change	Yes	211	29.26
Functional status ( years)	Appropriate	68	71.58
	Delay	15	15.79
	Regression	12	12.63
Developmental history ( years)	Working	488	77.96
	Ambulatory	87	13.89
	Bedridden	51	8.15
Adherence	Good	356	49.38
	Fair	177	24.55
	Poor	188	26.07
WHO clinical stage	I	237	32.87
	II	202	28.02
	III	170	23.58
	IV	112	15.53
Isoniazid preventive therapy	Yes	451	62.55
Cotrimoxazole preventive therapy	Yes	419	58.11
CD4 count	Below the threshold	308	42.72
Hemoglobin level	≤10 g/dl	229	31.76
ART eligibility criteria	Immunologic	81	11.23
	Clinical stage	96	13.31
	WHO clinical stage	79	10.96
	CD4 threshold	199	27.60
	Examine and treat	266	36.90
Type of opportunistic infection	Bacterial pneumonia	79	30.62
	Diarrhea	74	28.68
	Meningitis	9	3.49
	Pneumocystis pneumonia	6	2.32
	Skin dermatitis	7	2.71
	Kaposi’s sarcoma	5	1.94
	Acute/chronic otitis media	9	3.49
	Others	3	1.16
	Tuberculosis	66	25.59
Duration of ART	≤36 months	223	30.93
	37–72 months	295	40.92
	>72 months	203	28.15
Maternal PMTC follow-up history	Yes	487	67.55
MUAC	≤11.5 cm	270	37.45
Tuberculosis treatment history	Yes	66	9.15
Survival status of children	Died	87	12.07